Randy F. Sweis

Also affiliated with University of Chicago

MedicineImmunology and MicrobiologyBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 22 papers. Top paper: “Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study”.

Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study

The Lancet Oncology(2021)10.1016/s1470-2045(21)00241-2

N/A

5.2DataRank · unranked

186 citations

Amishi Y. Shah, Drew Rasco, Arpit Rao, Matthew H. Taylor, Christopher Di Simone +23 more

Germline genetic contribution to the immune landscape of cancer

Immunity(2021)10.1016/j.immuni.2021.01.011

N/A

4.2DataRank · unranked

178 citations

Mohamad Saad, Vésteinn Thórsson, Donglei Hu, Wouter Hendrickx, Jessica Roelands +21 more

Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma

New England Journal of Medicine(2024)10.1056/nejmoa2401726

N/A

3.9DataRank · unranked

151 citations

Karla V. Ballman, Guru Sonpavde, Stephanie Berg, William Y. Kim, Rahul Atul Parikh +35 more

Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-2824

N/A

0.656DataRank · unranked

22 citations

Randy F. Sweis, J. Randolph Hecht, Reva Schneider, Mark N. Stein, Talia Golan +7 more

A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma

European Urology Oncology(2024)10.1016/j.euo.2023.12.001

N/A

0.360DataRank · unranked

10 citations

Randy F. Sweis, Manojkumar Bupathi, Elisabeth Heath, Oscar B. Goodman, Christopher J. Hoimes +19 more

Hallmarks of Resistance to Immune-Checkpoint Inhibitors

Cancer Immunology Research(2022)10.1158/2326-6066.cir-20-0586

N/A

0DataRank · unranked

134 citations

Alexandria P. Cogdill, Paul B. Robbins, Michaela Bowden, Elizabeth M. Burton, Lisa H. Butterfield +17 more

A global method for fast simulations of molecular dynamics in multiscale agent-based models of biological tissues

iScience(2022)10.1016/j.isci.2022.104387

N/A

0DataRank · unranked

8 citations

Randy F. Sweis, Alexander T. Pearson, Fereshteh Nazari, Trachette L. Jackson, Daniel Bergman

Melanoma and microbiota: Current understanding and future directions

Cancer Cell(2023)10.1016/j.ccell.2023.12.003

N/A

0DataRank · unranked

82 citations

Tanisha Jackson, Laura Mählmann, Christina K. Baumgartner, Martin J. Blaser, Allyson L. Byrd +26 more

Mathematical model predicts tumor control patterns induced by fast and slow cytotoxic T lymphocyte killing mechanisms

Scientific Reports(2023)10.1038/s41598-023-49467-6

N/A

0DataRank · unranked

15 citations

Daniel Bergman, Erica Trujillo, Alexander T. Pearson, Randy F. Sweis, Trachette L. Jackson +1 more

FGFR3 Alterations in the Era of Immunotherapy for Urothelial Bladder Cancer

Frontiers in Immunology(2020)10.3389/fimmu.2020.575258

N/A

0DataRank · unranked

68 citations

Randy F. Sweis, Alec Kacew

Batf3+ DCs and the 4-1BB/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1/PD-L1 blockade efficacy

Cell Reports(2024)10.1016/j.celrep.2024.114141

N/A

0DataRank · unranked

23 citations

Brendan Horton, Emily F. Higgs, Ken Hatogai, Anna Martinez, Jason W. Shapiro +5 more

A Phase II Open-Label, Randomized Clinical Trial of Atezolizumab with or without Human Recombinant IL-7 (CYT107) in Advanced Urothelial Cancer

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-1728

N/A

0DataRank · unranked

7 citations

Gurkamal Chatta, Rohit K. Jain, Helen Moon, Scott E. Delacroix, Alana Fang +10 more

High tumor glucocorticoid receptor expression in early-stage, triple-negative breast cancer is associated with increased T-regulatory cell infiltration

Breast Cancer Research and Treatment(2024)10.1007/s10549-024-07515-3

N/A

0DataRank · unranked

8 citations

Christine Y. Shiang, Deniz Nesli Dolcen, Marie Dreyer, Ken Hatogai, Katie Hall +8 more

Dysregulated FGFR3 signaling alters the immune landscape in bladder cancer and presents therapeutic possibilities in an agent-based model

Frontiers in Immunology(2024)10.3389/fimmu.2024.1358019

N/A

0DataRank · unranked

7 citations

Yixuan Wang, Erica Trujillo, Anthony A. Fernald, Erguang Li, Alexander T. Pearson +3 more

A Validated Mathematical Model of FGFR3-Mediated Tumor Growth Reveals Pathways to Harness the Benefits of Combination Targeted Therapy and Immunotherapy in Bladder Cancer

(2024)10.22541/au.170664414.42348543/v1

N/A

0DataRank · unranked

0 citations

Daniel Bergman, Jeffrey Bloodworth, Alexander T. Pearson, Randy F. Sweis, Trachette L. Jackson +1 more

A Roadmap for the Future of Systems Biology in Cancer Research

Cancer Research(2025)10.1158/0008-5472.can-25-0700

N/A

0DataRank · unranked

2 citations

Carlos F. Lopez, Andréi S. Rodin, Russell C. Rockne, Thomas E. Yankeelov, Herbert M Sauro +23 more

PKCδ Germline Variants and Genetic Deletion in Mice Augment Antitumor Immunity through Regulation of Myeloid Cells

Cancer Immunology Research(2025)10.1158/2326-6066.cir-23-0999

N/A

0DataRank · unranked

1 citations

Ayelet Sivan, Keston Aquino-Michaels, Andrea Ziblat, Emily F. Higgs, Randy F. Sweis +4 more

Phase I trial of enzalutamide (Enz) plus the glucocorticoid receptor antagonist relacorilant (Rela) for patients with metastatic castration resistant prostate cancer.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5062

N/A

0DataRank · unranked

6 citations

Anthony V. Serritella, Walter M. Stadler, Peter H. O’Donnell, Randy F. Sweis, Russell Z. Szmulewitz +1 more

Morphological correlation of urinary bladder cancer molecular subtypes in radical cystectomies

Human Pathology(2020)10.1016/j.humpath.2020.09.010

N/A

0DataRank · unranked

10 citations

Alexander J. Gallan, Gary D. Steinberg, Randy F. Sweis, Gladell P. Paner, Lisa Han

Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-1963

N/A

0DataRank · unranked

369 citations

Randy F. Sweis, F. Stephen Hodi, Wells A. Messersmith, Robert H.I. Andtbacka, Matthew Ingham +11 more

A validated mathematical model of FGFR3‐mediated tumor growth reveals pathways to harness the benefits of combination targeted therapy and immunotherapy in bladder cancer

Computational and Systems Oncology(2021)10.1002/cso2.1019

N/A

0DataRank · unranked

17 citations

Daniel Bergman, Jeffrey Bloodworth, Alexander T. Pearson, Randy F. Sweis, Trachette L. Jackson +1 more

Severe COVID-19 infection is associated with aberrant cytokine production by infected lung epithelial cells rather than by systemic immune dysfunction

Research Square(2021)10.21203/rs.3.rs-1083825/v1

N/A

0DataRank · unranked

10 citations

Sherin J. Rouhani, Jonathan Trujillo, Athalia R. Pyzer, Jovian Yu, Jessica Fessler +28 more